Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Present And Forecasted Size Of The Candidiasis Therapeutics Market?
In the last couple of years, the size of the candidiasis therapeutics market has consistently risen. The market, which is set to grow from $3.19 billion in 2024 to $3.29 billion in 2025, will experience a compound annual growth rate (CAGR) of 3.0%. Factors that have contributed to growth during the historical period include a rise in candidiasis cases, the use of and resistance to antibiotics, infections acquired in hospitals, changes in fungal resistance trends, and initiatives for awareness and education.
The market for candidiasis therapeutics is projected to steadily increase in size over the upcoming years. It is estimated to reach a valuation of $3.83 billion in 2029, with a compound annual growth rate (CAGR) of 3.9%. The predicted growth within this time period is linked to precision medicine methods, global antifungal stewardship programs, the rising occurrence of candida auris, and worldwide efforts to combat antifungal resistance. Key trends for this forthcoming period include the progression of drug delivery technologies, the use of telemedicine and remote patient monitoring, patient-focused care, combination treatment methods, and collaborative research initiatives.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13182&type=smp
What Underlying Factors Are Supporting The Candidiasis Therapeutics Market Growth?
The candidiasis therapeutics market is poised for growth, driven by the escalating incidence of fungal infections. Fungal infections are diseases provoked by a variety of fungi, impacting human skin, mucous membranes, and internal organs. The increase in people with weakened immune systems and those with fungal infections augments the vulnerability to candidiasis. This provides room for manufacturers to create and provide more tailored and efficient antifungal drugs that can address the root fungi pathogens, alleviate symptoms, avert complications, aid patients in recovery, mitigate the transmission of Candida infections within healthcare facilities, and enhance patient outcomes. For example, the University of Minnesota, a well-known US research university, recorded in January 2024 that fungal infections result in over 3.75 million deaths per year, with roughly 2.55 million of these casualties being directly linked to fungal diseases. Consequently, the mounting occurrence of fungal infections will fuel the growth of the candidiasis therapeutics market.
How Does The Candidiasis Therapeutics Market Differ By Segment?
The candidiasis therapeuticsmarket covered in this report is segmented –
1) By Treatment Type: Medication; Surgery; Other Treatments
2) By Anatomy Type: Oral Candidiasis; Vulvovaginal Candidiasis; Cutaneous Candidiasis; Invasive Candidiasis; Systemic Candidiasis
3) By Mode Of Administration: Injectable; Oral; Other Mode Of Administrations
4) By Patient Population: Adults; Pediatrics
5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
Subsegments:
1) By Medication: Antifungal Drugs; Topical Treatments; Systemic Treatments
2) By Surgery: Surgical Debridement; Organ Removal
3) By Other Treatments: Probiotics; Home Remedies; Lifestyle Modifications
What Are The Dominant Trends Currently Seen In The Candidiasis Therapeutics Market?
Leading companies in the candidiasis therapeutics market are spearheading the creation of new drugs, like BREXAFEMME (ibrexafungerp tablets), aimed at curtailing the recurrent instances of vulvovaginal candidiasis (RVVC) or chronic yeast infections in adult women. This oral, non-azole medication is not only used for addressing vulvovaginal candidiasis (VVC) but also serves to curb its recurrent incidence. In December 2022, the US pharmaceutical enterprise, Scynexis Inc., was given the green light by the US Food and Drug Administration (FDA) for using BREXAFEMME (ibrexafungerp tablets) as a means to both treat VVC and diminish instances of recurring RVVC. The drug functions by thwarting the growth of Candida albicans – the culprit behind VVC. Additionally, it has proven to be a secure and efficacious option for VVC treatment. The drug requires a prescription, and the recommended daily dosage is a single 150-mg capsule, to be taken orally for one day.
Who Are The Global Leaders Steering The Candidiasis Therapeutics Market Forward?
Major companies operating in the candidiasis therapeutics market report are Pfizer Inc., Biocon Limited, Torrent Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc., GSK plc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Cipla Inc., Bruker Corporation, Lupin Limited, Galapagos NV, Basilea Pharmaceutica Ltd., WOCKHARDT Limited, Pacgen Life Science Corporation, Cidara Therapeutics Inc., Ablynx NV, Amplyx Pharmaceuticals Inc., NovaDigm Therapeutics Inc., SCYNEXIS Inc., Medivir AB, Mycovia Pharmaceuticals Inc., NovaBiotics Inc., Matinas BioPharma Holdings Inc.
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/candidiasis-therapeutics-global-market-report
Which Region Is Likely To Register The Fastest Growth In The Candidiasis Therapeutics Market?
North America was the largest region in the candidiasis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the candidiasis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=13182&type=smp
Browse Through More Reports Similar to the Global Candidiasis Therapeutics Market 2025, By The Business Research Company
Digital Therapeutics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/digital-therapeutics-global-market-report
Leukemia Therapeutics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report
Liver Diseases Therapeutics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model